Scope, Claims, and U.S. Patent Landscape for US Patent 6,136,794
What is the claimed invention in US 6,136,794?
US 6,136,794 claims pharmaceutical and treatment methods for inhibiting platelet aggregation by combination therapy using:
- a GPIIb/IIIa receptor antagonist (in claims 1, 2, 3, 4, 5), and
- low molecular weight heparin (LMWH) (in all independent/dependent method claim set you provided), and
- aspirin in claims 3 and 4.
Claim 5 adds a functional clinical outcome limitation tied to bleeding time versus unfractionated heparin (UFH).
The claims you provided define a drug regimen combination (method of treatment) rather than a specific dosage form, route, or administration schedule (those are typically supplied by the specification, but the claims as given focus on components and therapeutic effect).
What is the claim scope of the independent and dependent claims?
Claim 1: GPIIb/IIIa antagonist + LMWH
Claim 1:
“A method for inhibiting platelet aggregation in a mammal comprising administering… a safe and therapeutically effective amount of a GPIIb/IIIa receptor antagonist… and a safe and therapeutically effective amount of low molecular weight heparin.”
Scope drivers
- Method type: treatment method for inhibiting platelet aggregation.
- Target: platelet aggregation inhibition is the claimed therapeutic function.
- Active classes:
- “GPIIb/IIIa receptor antagonist” (broad class language)
- “low molecular weight heparin” (broad to LMWHs covered by the term as used in the art)
- Mammal: covers patients across mammals (includes humans in practice unless expressly limited).
What the claim covers (as drafted)
- Any GPIIb/IIIa antagonist that falls within the functional definition of receptor antagonist.
- Any LMWH that qualifies as “low molecular weight heparin” under the patent’s claim construction in U.S. practice.
What is not required (from the claim text provided)
- No mandatory aspirin.
- No explicit agent identity in claim 1.
- No explicit comparator or endpoint beyond the general therapeutic function.
Claim 2: Specific GPIIb/IIIa antagonist + LMWH
Claim 2 (depends from claim 1):
Method wherein the GPIIb/IIIa receptor antagonist is:
- (2-S-(n-butylsulfonylamino)-3[4-(piperidin-4-yl)butyloxyphenyl]propionic acid) or a pharmaceutically acceptable salt.
Scope drivers
- Narrows the GPIIb/IIIa antagonist from the broad class in claim 1 to a specific chemical entity (or its salts).
- Keeps the LMWH component.
Practical implication
- Claim 2 gives a fallback position if the broad class interpretation is contested. It also strengthens validity defensibility against prior art that uses other GPIIb/IIIa antagonists with LMWH.
Claim 3: Add aspirin
Claim 3 (depends from claim 1):
Method wherein the regimen includes:
- GPIIb/IIIa receptor antagonist
- LMWH
- aspirin
Scope drivers
- Requires triple therapy in the claimed method.
- Still does not limit the specific GPIIb/IIIa structure (unlike claim 4) or LMWH identity.
Practical implication
- Claim 3 is narrower than claim 1 but broader than claim 4 in that it accepts any GPIIb/IIIa antagonist.
Claim 4: Specific GPIIb/IIIa antagonist + LMWH + aspirin
Claim 4 (depends from claim 3):
Same as claim 3 but with the specific antagonist of claim 2.
Scope drivers
- Triple therapy with a single defined small-molecule antagonist.
Practical implication
- This is the tightest chemical-specification claim in the set you provided, and it likely has the strongest resistance to “other antagonist” design-arounds.
Claim 5: Bleeding-time reduction vs unfractionated heparin
Claim 5 (depends from claim 3 or claim set you provided as written):
Method for inhibiting platelet aggregation comprising administering a GPIIb/IIIa antagonist + LMWH, wherein:
- bleeding time is reduced relative to bleeding time associated with a method comprising administration of unfractionated heparin.
Scope drivers
- Adds a functional comparator limitation: bleeding time improvement relative to UFH.
- Defines the clinical property by comparison, not by absolute bleeding-time value.
Claim interpretation consequences
- Evidence of bleeding-time reduction becomes central to enforceability. In U.S. method claims with outcome limitations, practicing clinicians must be able to show the “relative reduction” consistent with the patented disclosure and claim construction.
- The claim does not require aspirin in its text as provided, which makes it a potential bridge between the claim set that includes aspirin and those that do not, depending on the dependency stated in the patent’s numbering.
How broad are “GPIIb/IIIa receptor antagonists” in this claim set?
The claims use class language: “a GPIIb/IIIa receptor antagonist.” That phrase typically captures antagonists that inhibit the GPIIb/IIIa receptor mediated platelet aggregation pathway.
From a landscape perspective, this class typically overlaps with marketed and clinical candidates in the GPIIb/IIIa space, including:
- peptide mimetics and related antagonists (many are large-molecule agents),
- small-molecule antagonists, and
- salts and polymorphic forms (claims allow “pharmaceutically acceptable salt” in the specific-entity claim set).
Two-scope structure created by the claim set
- Broad entry point via claim 1: any GPIIb/IIIa antagonist + LMWH.
- Narrow capture via claim 2/4: a particular chemical structure plus LMWH, with or without aspirin.
This structure is important for both infringement and invalidity:
- Infringement: a challenger can contest whether a rival agent is within “GPIIb/IIIa receptor antagonist” as construed. Even if they win that contest against claim 1, claim 2/4 can still land if the rival agent matches the specified chemical entity.
- Validity: prior art combinations with other GPIIb/IIIa antagonists may threaten claim 1 but be less relevant to claim 2/4.
How does the LMWH element constrain the claim set?
Claim language requires “low molecular weight heparin.” That term is generally interpreted in pharma practice to cover heparins with reduced chain lengths compared with UFH and commonly includes approved LMWH brands (e.g., enoxaparin, dalteparin, tinzaparin in the broader market).
Scope outcomes
- Design-around via switching to UFH is not a direct escape for claim 5 because claim 5 is explicitly framed relative to UFH. Switching to UFH would tend to remove the “LMWH” element and would likely fall outside claim language.
- Design-around via switching to non-heparin anticoagulants (e.g., direct thrombin inhibitors or factor Xa inhibitors) is likely to avoid the “LMWH” element, unless a substitute is argued to fall within “low molecular weight heparin” under claim construction.
Does aspirin addition create a distinct patentable regimen?
Claims 3 and 4 require aspirin in addition to GPIIb/IIIa antagonist and LMWH.
That matters because many platelet-directed treatment strategies already include aspirin. The legal differentiator here is:
- whether adding aspirin to the GPIIb/IIIa + LMWH combination is supported and non-obvious over existing dual-therapy regimens.
In litigation terms:
- If prior art already taught triple antiplatelet/anticoagulant regimens, claim 3/4 could face obviousness pressure.
- If prior art taught GPIIb/IIIa + aspirin but not with LMWH, or taught GPIIb/IIIa + LMWH but not aspirin, claim 3/4 can preserve distinctiveness.
How is “bleeding time reduced” used as a functional limiter?
Claim 5 requires a relative improvement:
- bleeding time reduced relative to bleeding time associated with UFH.
What this adds
- It creates a potential differentiator: even if GPIIb/IIIa + UFH or GPIIb/IIIa alone were known, the specific “LMWH vs UFH bleeding time reduction” narrative can support patentability and provide an enforcement hook.
What this complicates
- Enforceability may require clinical or preclinical demonstration aligned with what the patent discloses as the basis for the “reduced bleeding time” comparison.
U.S. Patent Landscape: where this claim set sits and what it must clear
What patent categories likely surround US 6,136,794?
Without relying on the full specification text, the claim set indicates the patent sits at the intersection of:
- Core GPIIb/IIIa receptor antagonist patents (composition and/or method claims for GPIIb/IIIa antagonists).
- Heparin class patents and LMWH-specific know-how (composition, process, and sometimes use claims).
- Combination therapy patents covering:
- GPIIb/IIIa antagonists with anticoagulants,
- antiplatelet combinations (aspirin),
- and clinically measured outcomes (bleeding time).
In a landscape review, the key risks are:
- obviousness over known combinations in cardiovascular/thrombotic indications,
- claim overlap with later-developed regimens once LMWH became standard,
- and obviousness of outcome claims if bleeding-time differences were routine expectations of switching UFH to LMWH.
How could competitors design around this patent?
Based strictly on claim language:
Design-arounds that likely reduce or eliminate infringement
- Use a non-LMWH anticoagulant instead of “low molecular weight heparin.”
- Use a GPIIb/IIIa antagonist that is not a “GPIIb/IIIa receptor antagonist” under claim construction (rare if the drug truly blocks the receptor, but possible for functional/partial modulators).
- Avoid the aspirin component to steer clear of claims 3 and 4 (but not claim 1 or 2, if those do not require aspirin).
- Use unfractionated heparin rather than LMWH (still likely infringes no “LMWH” element, and would also cut against claim 5’s LMWH/UFH comparison framing).
Design-arounds that likely fail against the core claims
- Keep LMWH and switch only dosing schedule: claims as provided do not require a specific schedule, only “administering” a therapeutically effective amount.
- Switch among GPIIb/IIIa antagonists while still using LMWH: claim 1 remains broad.
What claim elements are most vulnerable in validity challenges?
The principal vulnerability vectors:
- Combination obviousness
- If prior art already disclosed GPIIb/IIIa antagonists with heparin-like anticoagulants in platelet inhibition contexts, claim 1 may face invalidity pressure.
- Outcome-based limitation (bleeding time reduced)
- If bleeding-time improvement from LMWH vs UFH is known or predictable, claim 5 may be attacked as lacking non-obviousness over known anticoagulant substitution effects.
- Aspirin addition
- If aspirin was standard in the clinical setting for platelet aggregation inhibition, claim 3/4 could be attacked as an obvious augmentation to a known regimen.
Conversely, claim 2/4 benefit if the specified antagonist was not previously combined with LMWH in the relevant therapeutic context.
Claim-Chart Style Mapping (from the claims provided)
Claim 1 mapping
| Claim element |
Requirement from claim text |
| Method for inhibiting platelet aggregation |
“method for inhibiting platelet aggregation in a mammal” |
| Administer therapeutic agents |
“administering… a safe and therapeutically effective amount of…” |
| GPIIb/IIIa receptor antagonist |
“a GPIIb/IIIa receptor antagonist or a pharmaceutically acceptable salt” |
| Low molecular weight heparin |
“low molecular weight heparin” |
Claim 2 mapping
| Claim element |
Requirement |
| Specific antagonist |
(2-S-(n-butylsulfonylamino)-3[4-(piperidin-4-yl)butyloxyphenyl]propionic acid) or salt |
| Plus LMWH |
Includes “low molecular weight heparin” |
| Plus platelet aggregation inhibition method |
Same therapeutic function |
Claim 3 mapping
| Claim element |
Requirement |
| Triple regimen |
GPIIb/IIIa antagonist + LMWH + aspirin |
| Therapeutic intent |
“inhibiting platelet aggregation” |
| Mammal scope |
“in a mammal” |
Claim 4 mapping
| Claim element |
Requirement |
| Specific antagonist |
same defined chemical entity or salt |
| LMWH + aspirin |
required |
| Platelet aggregation inhibition |
required |
Claim 5 mapping
| Claim element |
Requirement |
| Regimen |
GPIIb/IIIa receptor antagonist + LMWH |
| Outcome qualifier |
“bleeding time is reduced relative to… unfractionated heparin” |
Key Takeaways
- US 6,136,794 claims method-of-treatment regimens centered on GPIIb/IIIa receptor antagonism combined with LMWH, with aspirin in claims 3 and 4.
- Claim 1 is the broadest, covering any GPIIb/IIIa receptor antagonist paired with LMWH for platelet aggregation inhibition.
- Claim 2 and claim 4 narrow the GPIIb/IIIa component to a specific chemical entity: (2-S-(n-butylsulfonylamino)-3[4-(piperidin-4-yl)butyloxyphenyl]propionic acid) or salt.
- Claim 5 adds a functional clinical comparator: reduced bleeding time versus UFH, which can distinguish the LMWH substitution but ties enforceability to evidence of that outcome.
- Design-arounds that change the LMWH element or the aspirin requirement are the cleanest routes around these specific claims; switching only the GPIIb/IIIa antagonist likely does not avoid claim 1.
FAQs
1) Does US 6,136,794 claim the composition of the GPIIb/IIIa antagonist or LMWH?
No. The claims you provided are method claims that require administering specified agents for platelet aggregation inhibition.
2) Is aspirin required for all claims?
No. Aspirin is required only in claims 3 and 4 as provided; claims 1, 2, and 5 do not require aspirin in the text you listed.
3) What is the main difference between claim 1 and claim 2?
Claim 1 covers any GPIIb/IIIa receptor antagonist, while claim 2 restricts that antagonist to a specific chemical entity (or salt).
4) How does claim 5 differ from the other claims?
Claim 5 adds a bleeding-time outcome limitation: reduced bleeding time versus a UFH-based method.
5) What is the most direct way to avoid infringement based on the claim text provided?
Avoid the “low molecular weight heparin” element, since LMWH is required in claims 1, 2, 3, 4, and 5 as provided.
References
[1] United States Patent 6,136,794. Method for inhibiting platelet aggregation using a GPIIb/IIIa antagonist and low molecular weight heparin (claims provided in prompt).
